Literature DB >> 9692431

Does arterial revascularization decrease the risk of infarction after coronary artery bypass grafting?

P T Sergeant1, E H Blackstone, B P Meyns.   

Abstract

BACKGROUND: This study sought to determine whether extensive arterial grafting reduces the prevalence and consequences of infarct after coronary artery bypass grafting.
METHODS: Post-primary coronary artery bypass grafting infarcts and time-related events thereafter were identified by 99.9% complete follow-up of 9,600 patients (1971 to 1992). The contribution of arterial grafting to freedom from infarct was assessed by multivariable hazard function analysis to adjust for other risk factors.
RESULTS: Unadjusted 1-month and 10-year freedom from infarction was 97% and 86%. By multivariable analysis, arterial grafting lowered the prevalence of periprocedural (p = 0.005), intermediate term (p = 0.007 and 0.006), and late infarction (arterial grafting to the left anterior descending coronary artery, p = 0.0006). Unadjusted survival after first infarct after coronary artery bypass grafting was 74% and 52% at 1 and 10 years; arterial grafting improved 10-year survival from 48% to 59% (p = 0.002). An additional benefit or cost of extending arterial grafting (n = 1,727) beyond a single one could not be identified (p > 0.1).
CONCLUSIONS: Arterial conduits, particularly to the left anterior descending coronary artery, should be used for coronary artery bypass grafting to reduce early and late myocardial infarction and its consequences. However, use of more than a single arterial graft appears to confer no additional benefit.

Entities:  

Mesh:

Year:  1998        PMID: 9692431     DOI: 10.1016/s0003-4975(98)00394-4

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Metabolic profiles predict adverse events after coronary artery bypass grafting.

Authors:  Asad A Shah; Damian M Craig; Jacqueline K Sebek; Carol Haynes; Robert C Stevens; Michael J Muehlbauer; Christopher B Granger; Elizabeth R Hauser; L Kristin Newby; Christopher B Newgard; William E Kraus; G Chad Hughes; Svati H Shah
Journal:  J Thorac Cardiovasc Surg       Date:  2012-02-04       Impact factor: 5.209

2.  Mortality and recurrent cardiac events after coronary artery bypass graft: long term outcomes in a population study.

Authors:  P J Bradshaw; K Jamrozik; M Le; I Gilfillan; P L Thompson
Journal:  Heart       Date:  2002-11       Impact factor: 5.994

3.  Arterial revascularization. 18-year experience with coronary artery bypass grafting in familial hypercholesterolemia.

Authors:  M Kawasuji; N Sakakibara; H Takemura; T Ushijima; M Ikeda; S Tabata; S Yamaguchi; Y Watanabe
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1999-07

4.  Hybrid Coronary Revascularization for the Treatment of Multivessel Coronary Artery Disease: A Multicenter Observational Study.

Authors:  John D Puskas; Michael E Halkos; Joseph J DeRose; Emilia Bagiella; Marissa A Miller; Jessica Overbey; Johannes Bonatti; V S Srinivas; Mark Vesely; Francis Sutter; Janine Lynch; Katherine Kirkwood; Timothy A Shapiro; Konstantinos D Boudoulas; Juan Crestanello; Thomas Gehrig; Peter Smith; Michael Ragosta; Steven J Hoff; David Zhao; Annetine C Gelijns; Wilson Y Szeto; Giora Weisz; Michael Argenziano; Thomas Vassiliades; Henry Liberman; William Matthai; Deborah D Ascheim
Journal:  J Am Coll Cardiol       Date:  2016-07-26       Impact factor: 24.094

5.  Reduced arterial elasticity due to surgical skeletonization is ameliorated by abluminal PEG hydrogel.

Authors:  Karyn G Robinson; Rebecca A Scott; Anne M Hesek; Edward J Woodford; Wafa Amir; Thomas A Planchon; Kristi L Kiick; Robert E Akins
Journal:  Bioeng Transl Med       Date:  2017-05-30

6.  Clinical results after hybrid coronary revascularization with totally endoscopic coronary surgery.

Authors:  Jade Claessens; Alaaddin Yilmaz; Camille Awouters; Hanne Oosterbos; Stef Thonnisen; Edouard Benit; Abdullah Kaya; Yoann Bataille
Journal:  J Cardiothorac Surg       Date:  2022-05-03       Impact factor: 1.522

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.